Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Contri

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
International Journal of Molecular Sciences|July 24, 2021
Adenosine and Inflammation: Here, There and EverywhereSilvia Pasquini, Chiara Contri, Pier Andrea Borea, et al.
Frontiers in Pharmacology|October 24, 2022
Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applicationsSilvia Pasquini, Chiara Contri, Martina Cappello, et al.
International Journal of Molecular Sciences|February 15, 2022
Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic TargetsSilvia Pasquini, Chiara Contri, Stefania Merighi, et al.
Cells|February 15, 2022
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation InhibitionAlessandro Papa, Silvia Pasquini, Chiara Contri, et al.
Biomolecules|June 28, 2023
Caffeine for Prevention of Alzheimer's Disease: Is the A<sub>2A</sub> Adenosine Receptor Its Target?Stefania Merighi, Alessia Travagli, Manuela Nigro, et al.
Biomolecules|September 28, 2023
Pharmacology of Adenosine Receptors: Recent AdvancementsFabrizio Vincenzi, Silvia Pasquini, Chiara Contri, et al.
Journal of Pineal Research|April 12, 2024
Binding and unbinding of potent melatonin receptor ligands: Mechanistic simulations and experimental evidenceAnnalida Bedini, Gian Marco Elisi, Fabiola Fanini, et al.
Archiv Der Pharmazie|September 26, 2023
Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agentsAlessandro Papa, Ilaria Cursaro, Luca Pozzetti, et al.
Chemmedchem|October 4, 2022
Synthesis of Unsymmetrical Squaramides as Allosteric GSK-3β Inhibitors Promoting β-Catenin-Mediated Transcription of TCF/LEF in Retinal Pigment Epithelial CellsGabriele Carullo, Laura Bottoni, Silvia Pasquini, et al.
European Journal of Medicinal Chemistry|December 3, 2022
Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditionsAlessandro Papa, Silvia Pasquini, Francesca Galvani, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
International Journal of Molecular Sciences|July 24, 2021
Adenosine and Inflammation: Here, There and EverywhereSilvia Pasquini, Chiara Contri, Pier Andrea Borea, et al.
Frontiers in Pharmacology|October 24, 2022
Update on the recent development of allosteric modulators for adenosine receptors and their therapeutic applicationsSilvia Pasquini, Chiara Contri, Martina Cappello, et al.
International Journal of Molecular Sciences|February 15, 2022
Adenosine Receptors in Neuropsychiatric Disorders: Fine Regulators of Neurotransmission and Potential Therapeutic TargetsSilvia Pasquini, Chiara Contri, Stefania Merighi, et al.
Cells|February 15, 2022
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation InhibitionAlessandro Papa, Silvia Pasquini, Chiara Contri, et al.
Biomolecules|June 28, 2023
Caffeine for Prevention of Alzheimer's Disease: Is the A<sub>2A</sub> Adenosine Receptor Its Target?Stefania Merighi, Alessia Travagli, Manuela Nigro, et al.
Biomolecules|September 28, 2023
Pharmacology of Adenosine Receptors: Recent AdvancementsFabrizio Vincenzi, Silvia Pasquini, Chiara Contri, et al.
Journal of Pineal Research|April 12, 2024
Binding and unbinding of potent melatonin receptor ligands: Mechanistic simulations and experimental evidenceAnnalida Bedini, Gian Marco Elisi, Fabiola Fanini, et al.
Archiv Der Pharmazie|September 26, 2023
Pioneering first-in-class FAAH-HDAC inhibitors as potential multitarget neuroprotective agentsAlessandro Papa, Ilaria Cursaro, Luca Pozzetti, et al.
Chemmedchem|October 4, 2022
Synthesis of Unsymmetrical Squaramides as Allosteric GSK-3β Inhibitors Promoting β-Catenin-Mediated Transcription of TCF/LEF in Retinal Pigment Epithelial CellsGabriele Carullo, Laura Bottoni, Silvia Pasquini, et al.
European Journal of Medicinal Chemistry|December 3, 2022
Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditionsAlessandro Papa, Silvia Pasquini, Francesca Galvani, et al.
Pageof 2